![Kris Motmans](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kris Motmans
Directeur/Bestuurslid bij SEPS Pharma NV
Actieve functies van Kris Motmans
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SEPS Pharma NV
![]() SEPS Pharma NV Pharmaceuticals: GenericHealth Technology SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium. | Directeur/Bestuurslid | 10-02-2010 | - |
Apitope Technology (Bristol) Ltd.
![]() Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Directeur/Bestuurslid | 01-06-2010 | - |
Medinvents NV
![]() Medinvents NV Medical SpecialtiesHealth Technology Medinvents NV engages in the manufacture of biopsy surgical instruments. The company was founded on December 28, 1992 and is headquartered in Hasselt, Belgium. | Directeur/Bestuurslid | 23-04-2016 | - |
Loopbaan van Kris Motmans
Eerdere bekende functies van Kris Motmans
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MUbio Holding BV
![]() MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Directeur/Bestuurslid | 01-06-2010 | 05-06-2013 |
Life Sciences Development Campus NV
![]() Life Sciences Development Campus NV Miscellaneous Commercial ServicesCommercial Services Life Sciences Development Campus NV provides research and development services in the field of biomedical life sciences. The company is headquartered in Abis, BelGium. | Directeur/Bestuurslid | - | - |
Algemeen Directeur | - | - | |
Voorzitter | - | - | |
Puilaetco | Analyst-Equity | - | - |
TIGENIX NV | Public Communications Contact | 24-08-2010 | - |
Life Sciences Consultancy | Oprichter | - | - |
Allux Medical, Inc.
![]() Allux Medical, Inc. Medical SpecialtiesHealth Technology Allux Medical, Inc., a medical device company, develops devices to locally modulate the immune system for the treatment of inflammatory diseases. The company was founded in 2004 by a medical doctor Michael Gertner and a serial entrepreneur Erica Rogers and is based in Menlo Park, California. | Oprichter | - | - |
░░░░░░░ ░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Opleiding van Kris Motmans
Ghent University | Doctorate Degree |
Hasselt University | Doctorate Degree |
Statistieken
Internationaal
België | 7 |
Verenigde Staten | 3 |
Verenigd Koninkrijk | 3 |
Operationeel
Director/Board Member | 5 |
Doctorate Degree | 2 |
Founder | 2 |
Sectoraal
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
JOHNSON & JOHNSON | Health Technology |
Bedrijven in privébezit | 9 |
---|---|
SEPS Pharma NV
![]() SEPS Pharma NV Pharmaceuticals: GenericHealth Technology SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Allux Medical, Inc.
![]() Allux Medical, Inc. Medical SpecialtiesHealth Technology Allux Medical, Inc., a medical device company, develops devices to locally modulate the immune system for the treatment of inflammatory diseases. The company was founded in 2004 by a medical doctor Michael Gertner and a serial entrepreneur Erica Rogers and is based in Menlo Park, California. | Health Technology |
Apitope Technology (Bristol) Ltd.
![]() Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Commercial Services |
Life Sciences Consultancy | |
MUbio Holding BV
![]() MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Health Technology |
TiGenix NV
![]() TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
Puilaetco | Finance |
Life Sciences Development Campus NV
![]() Life Sciences Development Campus NV Miscellaneous Commercial ServicesCommercial Services Life Sciences Development Campus NV provides research and development services in the field of biomedical life sciences. The company is headquartered in Abis, BelGium. | Commercial Services |
Medinvents NV
![]() Medinvents NV Medical SpecialtiesHealth Technology Medinvents NV engages in the manufacture of biopsy surgical instruments. The company was founded on December 28, 1992 and is headquartered in Hasselt, Belgium. | Health Technology |
- Beurs
- Insiders
- Kris Motmans
- Ervaring